AKT1 and paracoccidioidomycosis: However, development work, and clinical trials continue, including studies using signal transduction pathway inhibitors [58], and the PI3K/AKT/mTOR, MAPK, JAK-STAT, and NFκB pathways, which are activated in PCM, are under investigation.